ATYR PHARMA INCATYR PHARMA INCATYR PHARMA INC

ATYR PHARMA INC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪108.09 M‬EUR
−0.84EUR
‪−45.65 M‬EUR
‪319.82 K‬EUR
‪66.88 M‬
Beta (1Y)
1.29

About aTyr Pharma, Inc.

CEO
Sanjay S. Shukla
Headquarters
San Diego
Employees (FY)
59
Founded
2005
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 471A is 1.64 EUR — it has increased by 3.14% in the past 24 hours. Watch ATYR PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ATYR PHARMA INC stocks are traded under the ticker 471A.
ATYR PHARMA INC is going to release the next earnings report on Aug 14, 2024. Keep track of upcoming events with our Earnings Calendar.
471A stock is 3.12% volatile and has beta coefficient of 1.29. Track ATYR PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is ATYR PHARMA INC there?
471A earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.23 EUR resulting in a 8.00% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about ATYR PHARMA INC earnings.
ATYR PHARMA INC revenue for the last quarter amounts to ‪217.79 K‬ EUR despite the estimated figure of ‪33.98 K‬ EUR. In the next quarter revenue is expected to reach ‪37.07 K‬ EUR.
Yes, you can track ATYR PHARMA INC financials in yearly and quarterly reports right on TradingView.
471A stock has risen by 4.46% compared to the previous week, the month change is a 0.61% fall, over the last year ATYR PHARMA INC has showed a 24.07% decrease.
471A net income for the last quarter is ‪−14.36 M‬ EUR, while the quarter before that showed ‪−13.37 M‬ EUR of net income which accounts for −7.36% change. Track more ATYR PHARMA INC financial stats to get the full picture.
Today ATYR PHARMA INC has the market capitalization of ‪108.73 M‬, it has increased by 2.11% over the last week.
No, 471A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 471A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ATYR PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
471A reached its all-time high on Sep 23, 2021 with the price of 10.90 EUR, and its all-time low was 1.02 EUR and was reached on Nov 16, 2023. View more price dynamics on 471A chart.
See other stocks reaching their highest and lowest prices.
As of May 14, 2024, the company has 59.00 employees. See our rating of the largest employees — is ATYR PHARMA INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ATYR PHARMA INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ATYR PHARMA INC stock shows the sell signal. See more of ATYR PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ATYR PHARMA INC future price: according to them, 471A price has a max estimate of 32.24 EUR and a min estimate of 14.74 EUR. Watch 471A chart and read a more detailed ATYR PHARMA INC stock forecast: see what analysts think of ATYR PHARMA INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ATYR PHARMA INC EBITDA is ‪−51.91 M‬ EUR, and current EBITDA margin is ‪−14.78 K‬%. See more stats in ATYR PHARMA INC financial statements.